Abstract:Background: Decreased function and reduced number of CD4+CD25+ regulatory T cells have been considered the major manifestation of immunity dysfunction in asthma patients. Mesenchymal stem cells (MSCs) have effects of immunoregulation, which can up-regulate CD4+CD25+ regulatory T cells, inhibit proliferation of lymphocytes, and have been widely used in many immune diseases. Objective: To study the effect of bone marrow mesenchymal stem cell (BMSC) transplantation on the CD4+CD25+ regulatory T cells of peripheral blood and the airway inflammation in asthmatic mice. Design, time and setting: The randomized controlled animal experiment was performed at the Central Laboratory, Second Affiliated Hospital, Sun Yat-sen University from September 2006 to May 2008. Materials: Thirty-four SPF BALB/c mice were selected for this study. Of them, 4 male mice aged 3-4 weeks were used for preparing BMSCs. Thirty female mice aged six weeks were equally and randomly divided into normal control, model control and cell transplantation groups. Methods: Mice in the model control and cell transplantation groups were sensitized with 0.2 mL 500 mg/L ovalbumin (OVA) by a combination of intraperitoneal injection and repeated 50 g/L OVA solution challenges to establish the mouse asthma model. In the normal control group, normal saline of the equal volume was given instead of OVA. Mice in the cell transplantation group were intravenously administered MSCs at 10 days after sensitization. Main outcomes measures: The number of CD4+CD25+ regulatory T cells in peripheral blood was detected by flow cytometry. The total cell number of bronchoalveolar lavage fluid, the number of eosinophils, lymphocytes and neutrophils were counted to analyze the degree of inflammation of the airway together with pathological section. Results: Compared to the normal control group, the number of CD4+CD25+ regulatory T cells in peripheral blood was significantly decreased in the model control group (t=7.742, P < 0.05). Compared to the model control group, the number of CD4+CD25+ regulatory T cells in peripheral blood was significantly increased in the cell transplantation group (t=7.455, P < 0.05). There were significantly differences in the total cell number of bronchoalveolar lavage fluid, the number of eosinophils, lymphocytes and neutrophils (P < 0.05). The total cell number of bronchoalveolar lavage fluid was higher in the model control group compared with the normal control group (P < 0.05). The total cell number of bronchoalveolar lavage fluid was lower in the cell transplantation group compared to the model control group (P < 0.05). There was no obvious infiltration of inflammatory cells in the airways in the normal control group. However, there were a great number of inflammatory cells, epithelial proliferation, partial breakage and defluvium of the airway epithelium in the bronchus, below the vessel mucous membrane and around lung tissues in the model control group. Airway inflammation was significantly relieved in the cell transplantation group. Conclusions: MSCs via intravenous infusion can up-regulate CD4+CD25+ regulatory T cells of peripheral blood in asthmatic mice and relieve the inflammation of the lung in asthmatic mice.

The Genes Involved in Asthma with the Treatment of Human Embryonic Stem Cell-Derived Mesenchymal Stem Cells.

Immunomodulative Effects of Mesenchymal Stem Cells Derived from Human Embryonic Stem Cells in Vivo and in Vitro

Human Pluripotent Stem Cell-Derived Mesenchymal Stem Cells Prevent Chronic Allergic Airway Inflammation Via TGF-β1-Smad2/Smad3 Signaling Pathway in Mice.

Mesenchymal Stem Cells Derived from Human Induced Pluripotent Stem Cells Modulate T-cell Phenotypes in Allergic Rhinitis

Human Pluripotent Stem Cell-Derived Mesenchymal Stem Cells Prevent Allergic Airway Inflammation in Mice

Proteomic Analysis of Human Wharton’s Jelly Mesenchymal Stem/stromal Cells and Human Amniotic Epithelial Stem Cells: a Comparison of Therapeutic Potential

Gingival-derived Mesenchymal Stem Cells Alleviate Allergic Asthma Inflammation Via HGF in Animal Models

Therapeutic Effects of Human Pluripotent Stem Cell-Derived Mesenchymal Stem Cells on a Murine Model of Acute Type-2-Dominated Airway Inflammation

Human Ipsc-Mscs Prevent Steroid-Resistant Neutrophilic Airway Inflammation Via Modulating Th17 Phenotypes

Mesenchymal Stem Cells Suppress Severe Asthma by Directly Regulating Th2 Cells and Type 2 Innate Lymphoid Cells

Human embryonic stem cell-derived mesenchymal stromal cells suppress inflammation in mouse models of rheumatoid arthritis and lung fibrosis by regulating T-cell function

The MicroRNAs Involved in Asthma Following Mesenchymal Stem Cell Treatment.

Effect of Transfected Induced Pluripotent Stem Cells with Decorin Gene on Control of Lung Remodeling in Allergic Asthma.

The Lncrnas Involved in Mouse Airway Allergic Inflammation Following Induced Pluripotent Stem Cell-Mesenchymal Stem Cell Treatment

Dynamic transcriptional and epigenomic reprogramming from pediatric nasal epithelial cells to induced pluripotent stem cells

MiR-146a-5p engineered hucMSC-derived extracellular vesicles attenuate Dermatophagoides farinae-induced allergic airway epithelial cell inflammation

Mesenchymal Stem Cells Abrogate Experimental Asthma by Altering Dendritic Cell Function

Effects of bone marrow mesenchymal stem cells on CD4+CD25+ regulatory T cells and airway inflammation in asthmatic mice

Mesenchymal Stem Cells Overexpressing Interleukin-10 Prevent Allergic Airway Inflammation

Characterization and Therapeutic Application of Mesenchymal Stem Cells with Neuromesodermal Origin from Human Pluripotent Stem Cells

Small Extracellular Vesicles Derived From Human Mscs Prevent Allergic Airway Inflammation Via Immunomodulation On Pulmonary Macrophages